These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17826266)

  • 21. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
    Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
    Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
    But WM; Lee SH; Chan AO; Lau GT
    Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
    Verloes A; Massin M; Lombet J; Grattagliano B; Soyeur D; Rigo J; Koulischer L; Van Hoof F
    Am J Med Genet; 1997 Oct; 72(2):135-42. PubMed ID: 9382133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immortalization of murine muscle cells from lysosomal alpha-glucosidase deficient mice: a new tool to study pathophysiology and assess therapeutic strategies for Pompe disease.
    Douillard-Guilloux G; Mouly V; Caillaud C; Richard E
    Biochem Biophys Res Commun; 2009 Oct; 388(2):333-8. PubMed ID: 19665008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification.
    Huang HP; Chen PH; Hwu WL; Chuang CY; Chien YH; Stone L; Chien CL; Li LT; Chiang SC; Chen HF; Ho HN; Chen CH; Kuo HC
    Hum Mol Genet; 2011 Dec; 20(24):4851-64. PubMed ID: 21926084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report.
    Castellar-Leones SM; Ortiz-Corredor F; Manrique-Hernández D; Sánchez-Peñarete D; Ruiz-Ospina E; Soto-Peña D; Correa-Arrieta C
    J Med Case Rep; 2024 Jul; 18(1):328. PubMed ID: 39020349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights into therapeutic options for Pompe disease.
    Richard E; Douillard-Guilloux G; Caillaud C
    IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late form of Pompe disease with glycogen storage in peripheral nerves axons.
    Fidziańska A; Ługowska A; Tylki-Szymańska A
    J Neurol Sci; 2011 Feb; 301(1-2):59-62. PubMed ID: 21109266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation.
    Shemesh A; Wang Y; Yang Y; Yang GS; Johnson DE; Backer JM; Pessin JE; Zong H
    Am J Physiol Regul Integr Comp Physiol; 2014 Nov; 307(10):R1251-9. PubMed ID: 25231351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.
    Ashe KM; Taylor KM; Chu Q; Meyers E; Ellis A; Jingozyan V; Klinger K; Finn PF; Cooper CG; Chuang WL; Marshall J; McPherson JM; Mattaliano RJ; Cheng SH; Scheule RK; Moreland RJ
    Mol Genet Metab; 2010 Aug; 100(4):309-15. PubMed ID: 20554235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
    Meena NK; Raben N
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
    Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
    Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in diagnosis and management of Pompe disease.
    Davison JE
    J Mother Child; 2020 Oct; 24(2):3-8. PubMed ID: 33554498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II.
    Bijvoet AG; Van Hirtum H; Kroos MA; Van de Kamp EH; Schoneveld O; Visser P; Brakenhoff JP; Weggeman M; van Corven EJ; Van der Ploeg AT; Reuser AJ
    Hum Mol Genet; 1999 Nov; 8(12):2145-53. PubMed ID: 10545593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.